SCHEMBL1033640

SCHEMBL1033640

CCCNCCOc1ccc(NS(=O)(=O)c2ccc(OCC(F)F)cc2)c(C)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.39
SQSTM1 Q13501 1/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
MAPT P10636 3/20 0.39
KDM4E B2RXH2 2/20 0.39
LMNA P02545 7/20 0.38
HTT P42858 6/20 0.38
TSHR P16473 4/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
ALDH1A1 P00352 4/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
TP53 P04637 2/20 0.36
NPSR1 Q6W5P4 2/20 0.35
GAA P10253 2/20 0.35
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4244176 0.99 PKM (0.39) PKMSQSTM1KEAP1NFE2L2MAPT
SCHEMBL1029498 0.89 KIT (0.41) PKMSQSTM1KEAP1NFE2L2MAPT
SCHEMBL1030310 0.89 TSHR (0.41) PKMSQSTM1KEAP1NFE2L2MAPT
Hydrochloric Acid SCHEMBL4243947 0.89 KIT (0.41) PKMSQSTM1KEAP1NFE2L2MAPT
SCHEMBL1033689 0.88 PKM (0.43) PKMSQSTM1KEAP1NFE2L2MAPT
Hydrochloric Acid SCHEMBL4246986 0.88 TSHR (0.40) PKMSQSTM1KEAP1NFE2L2MAPT
Hydrochloric Acid SCHEMBL4251154 0.87 PKM (0.42) PKMSQSTM1KEAP1NFE2L2MAPT
SCHEMBL1033616 0.86 PKM (0.39) PKMSQSTM1KEAP1NFE2L2MAPT
Hydrochloric Acid SCHEMBL4240512 0.86 PKM (0.39) PKMSQSTM1KEAP1NFE2L2MAPT
SCHEMBL1031574 0.85 CCR9 (0.44) PKMSQSTM1KEAP1NFE2L2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013179-B1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO KG (DE) 2011-01-19 EP disclosed